Table 3.
Patients with viral breakthrough.
ETV | LAM | |||
---|---|---|---|---|
Adherence rate | ≥90% | <90% | ≥90% | <90% |
Resistance mutation (+) | 1 | 1 | 31 | 1 |
L180M | 1 | 1 | N.D. | N.D. |
T184A | 1 | 0 | N.D. | N.D. |
S202G | 0 | 1 | N.D. | N.D. |
M204V | 1 | 1 | 9 | 1 |
M204I | 0 | 0 | 17 | 0 |
M204V/I | 0 | 0 | 5 | 0 |
M250V | 0 | 0 | N.D. | N.D. |
Resistance mutation (-) | 1 | 1 | 0 | 2 |
ETV, entecavir; LAM, lamivudine; N.D., not determined. Numbers of amino acid positions were according to Refs. 2 and 10.